Strength Training Response of Muscle in GLP-1 Users
ConditionMuscle Mass
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorVirginia Polytechnic Institute and State University
About this trial
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Eligibility criteria
Qualifiers
Age, 50y+
Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
Weight <300 lb
Pass a health and exercise readiness screening
Disqualifiers
Age <50
Weight >300 lb
Osteoporosis
Active metabolic, neoplastic, or cardiovascular disease
Trial design
Treatments tested in this trial
- Strength Training
- Wait first, then strength training
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov